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CD146/MCAM defines functionality of
human bone marrow stromal stem cell
populations
Linda Harkness1* , Walid Zaher1,3, Nicholas Ditzel1, Adiba Isa1 and Moustapha Kassem1,2,3
Abstract
Background: Identification of surface markers for prospective isolation of functionally homogenous populations of
human skeletal (stromal, mesenchymal) stem cells (hMSCs) is highly relevant for cell therapy protocols. Thus, we
examined the possible use of CD146 to subtype a heterogeneous hMSC population.
Methods: Using flow cytometry and cell sorting, we isolated two distinct hMSC-CD146+ and hMSC-CD146− cell
populations from the telomerized human bone marrow-derived stromal cell line (hMSC-TERT). Cells were examined
for differences in their size, shape and texture by using high-content analysis and additionally for their ability to
differentiate toward osteogenesis in vitro and form bone in vivo, and their migrational ability in vivo and in vitro was
investigated.
Results: In vitro, the two cell populations exhibited similar growth rate and differentiation capacity to osteoblasts
and adipocytes on the basis of gene expression and protein production of lineage-specific markers. In vivo, hMSC-
CD146+ and hMSC-CD146− cells formed bone and bone marrow organ when implanted subcutaneously in
immune-deficient mice. Bone was enriched in hMSC-CD146− cells (12.6 % versus 8.1 %) and bone marrow elements
enriched in implants containing hMSC-CD146+ cells (0.5 % versus 0.05 %). hMSC-CD146+ cells exhibited greater
chemotactic attraction in a transwell migration assay and, when injected intravenously into immune-deficient mice
following closed femoral fracture, exhibited wider tissue distribution and significantly increased migration ability as
demonstrated by bioluminescence imaging.
Conclusion: Our studies demonstrate that CD146 defines a subpopulation of hMSCs capable of bone formation
and in vivo trans-endothelial migration and thus represents a population of hMSCs suitable for use in clinical
protocols of bone tissue regeneration.
Keywords: Bone marrow stem cells, CD146/MCAM, Osteogenic differentiation, Bone formation
Background
Human bone marrow (BM) skeletal stem cells (also termed
marrow stromal cells or mesenchymal stem cells) (hMSCs)
are multipotent stem cells present in the BM stroma and
are capable of mesoderm lineage differentiation (e.g., osteo-
blasts, adipocytes, and chondrocytes) [1]. hMSCs are being
tested for treatment in a number of degenerative diseases,
including bone [2, 3] and cartilage [4] regeneration. hMSCs
isolated and expanded under current culture conditions
that rely on plastic adherence are heterogeneous with re-
spect to differentiation. Single-cell cloning of hMSCs re-
vealed that approximately 20–40 % of the cell population
are multipotent MSCs and the remaining are probably cells
at different stages of differentiation [5, 6]. In addition,
Russell et al. reported that only 50 % of clonal BM hMSCs
exhibited tri-lineage differentiation (osteoblasts, adipocytes,
and chondrocytes) [7]. We recently reported that canonical
osteoblastic markers (e.g., alkaline phosphate and osteocal-
cin) are not predictive for in vivo bone-forming capacity of
hMSCs or hMSC “stemness” [8] and that there exist, in
MSC cultures, cell populations committed to adipocyte or
osteoblast lineages [9]. More recently, lineage-tracing
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studies in vivo have corroborated the presence of hetero-
geneity within the MSC population [10]. This functional
heterogeneity of hMSCs limits the clinical use of MSCs in
therapy and may explain the varied results obtained from
clinical trials [11, 12]. Thus, one of the challenges facing
the use of hMSCs in therapy is the identification of pro-
spective markers that predict their in vivo functionality.
A number of studies have isolated and characterized
distinct populations of BM hMSCs by using a number of
surface markers (e.g., Stro-1 and CD105 [13], CD271 [14],
and CD56 [15, 16], and alkaline phosphatase (ALP) [17]).
Although these markers enrich for an hMSC population
with trilineage differentiation and colony-forming abilities,
the isolated cells were still heterogeneous with respect to
differentiation potential.
Cluster of differentiation 146 (CD146), also known as
melanoma cell adhesion molecule (MCAM, MelCAM) or
cell surface glycoprotein Muc18, was originally identified as
an endothelial cell marker with a role in cell-matrix inter-
action and angiogenesis. CD146 defines the self-renewing
hMSC population located in perivascular space in BM [18].
Additionally, CD146 expression has been reported to be
higher in hMSC multipotent clones compared with hMSC
unipotent clones [7] and to be correlated with osteoblastic
differentiation potential [18, 19]. Conversely, Tormin et al.
[14] reported that multipotent hMSCs are present in both
the CD146− and CD146+ populations and that these popu-
lations exist within two different niches in vivo: endosteal
and perivascular. Thus, differences and similarities of the
CD146− and CD146+ populations of hMSCs have not been
totally clarified.
We have previously established a human telomerase-
overexpressing hMSC line (termed hMSC-TERT [20])
that maintains “stemness” characteristics of hMSCs in
spite of extensive in vitro proliferation. hMSC-TERT
exhibit a mixed expression of CD146 and thus provided
us with the opportunity to characterize, in a prospective
fashion, the phenotype of hMSCs defined by CD146 ex-
pression. Here, we compare the biological characteristics
of CD146+ and CD146− cell populations by employing
in vitro and in vivo assays.
Methods
Cell cultures
We employed the parental telomerised cell line hMSC-
TERT (subclone hMSC-TERT4) described previously
[20]. To visualize the cells when implanted in vivo, we
created a sub-line from hMSC-TERT4, overexpressing
firefly luciferase (LUC2) and termed hMSC-LUC2.
Stable retroviral transfection using the firefly luciferase
gene LUC2
The LUC2 gene was polymerase chain reaction (PCR)-
amplified from the pGL4.10 plasmid by using Phusion Hot
Start High-Fidelity DNA Polymerase (Thermo Fisher Scien-
tific, Waltham, MA, USA) in accordance with the instruc-
tions of the manufacturer. The primers sequences were as
follows: forward primer: CATCAGCCAGCCCACCGTCG
and reverse primer: CGGTCGAAGCTCTCGGGCAC.
The PCR products were purified with the SV gel and
PCR clean-up system (Promega, Nacka, Sweden) and li-
gated into the retroviral vector pBABEpuro, which was
pre-digested with the SnaBI (blunt) restriction enzyme.
The plasmid was then transformed into DH5α cells. Posi-
tive clones were identified by purifying the vector by using
a Wizard® Plus SV Minipreps DNA Purification System
(Promega) in accordance with the instructions of the
manufacturer. After purification, the plasmid was linear-
ized and analyzed on a 0.5 % agarose gel for 90 min at
70 V. Finally, the inserts were confirmed by sequencing.
Virus generation and transfection
Phoenix A packaging cells (70–80 % confluent), cultured
in six-well plates, were transfected with the pBABE-LUC2
construct (3 μg/well) by using the FuGENE 6 (Roche, Hvi-
dovre, Denmark) method in accordance with the instruc-
tions of the manufacturer. The supernatants, from 25 cm2
of Phoenix A packaging cells containing virus particles,
were collected 24 and 48 h after transfection, filtered with
a 0.45-μm filter, diluted 1:1 with the culture medium, and
added to the hMSC-TERT cell line, in a 25-cm2 flask sup-
plemented with 6 μg/ml Polybrene for infection. Twenty-
four hours after the second round of infection, 3 μg/ml
puromycin was added for selection, and the selection
pressure was maintained until all non-transfected control
cells were eradicated. The puromycin-resistant cells were
expanded and maintained in medium supplemented with
0.2 μg/ml puromycin. An estimated 500,000 cells initially
survived the selection to make the respective cell line
(termed hMSC-LUC2).
CD146 cell sorting
The hMSC-LUC2, was used for all experiments. hMSC-
LUC2 cells were sorted on a FACSdiva (BD Biosciences,
Brøndby, Denmark) into positive (hMSC-CD146+) and
negative (hMSC-CD146–) cell populations using incuba-
tion with a PE pre-conjugated CD146 antibody (BD
Pharmingen, Brøndby, Denmark). Briefly, hMSC-LUC2
cells were trypsinized to a single-cell suspension, washed
in phosphate-buffered saline (PBS) with 0.5 % bovine
serum albumin (BSA), and incubated with CD146 anti-
body diluted in PBS with 0.5 % BSA for 30 min on ice.
Cells were then sorted into distinct populations on a
FACSAria cell sorter (BD Biosciences) and re-cultured
for future in vitro and in vivo experiments. Cell expan-
sion was performed in basal media (minimum essential
medium) (Invitrogen, Taastrup, Denmark with 10 % fetal
bovine serum (FBS); PAA, Pasching, Austria).
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Cell proliferation
Cell proliferation was monitored by determining the
number of population doublings by using the formula:
logN/log2, where N is the cell number of the confluent
monolayer divided by the initial number of seeded cells.
Cell differentiation
For osteoblast differentiation, the cells were cultured in
osteoblastic induction media (OIM) comprised of basal
media supplemented with 10 mM β-glycerophosphate
(Calbiochem-Merck, Darmstadt, Germany), 50 μg/ml L-
ascorbic acid-2-phosphate (Wako Chemicals GmbH,
Neuss, Germany), 10 nM dexamethasone (Sigma-Al-
drich, Brøndby, Denmark), and 10 nM calcitriol (1.25-di-
hydroxy vitamin-D3 (1,25 (OH)2D3) kindly provided by
Leo Pharma, Ballerup, Denmark). For adipocyte differen-
tiation, the cells were cultured in adipocytic induction
media (AIM) containing basal media supplemented with
10 % horse serum (Sigma-Aldrich), 100 nM dexametha-
sone (Sigma-Aldrich), 500 μM 1-methyl-3-isobutyl-
xanthine (IBMX) (Sigma-Aldrich), 1 μM Rosiglitazone
(BRL49653; Cayman Chemical, Ann Arbor, MI, USA),
and 5 μg/ml insulin (Sigma-Aldrich). Samples undergo-
ing induction were collected at days 5, 10, and 15. Three
independent experiments were performed for each dif-
ferentiation assay.
Flow cytometry
Flow cytometry was performed by using a FACScan (BD
Biosciences). To confirm the profile of either hMSC-TERT
versus hMSC-LUC2 or hMSC-CD146+ and hMSC-CD146–
populations, cells were trypsinized to a single-cell suspen-
sion, washed in PBS + 0.5 % BSA, and incubated with an
antibody (in PBS + 0.5 % BSA) for 30 min on ice. After
incubation, excess antibody was washed out by using PBS
and cells analyzed on the FACSCalibur (BD Biosciences)
flow cytometer and data analyzed by using WinMDI (The
Scripps Institute, Flow Cytometry Core Facility). Sorted and
unsorted cell populations were profiled using a number of
known MSC pre-conjugated fluorescence-activated cell
sorting (FACS) markers: CD14-FITC, CD34-PE, CD44-PE,
CD63-FITC, CD73-PE, and CD146-PE (all BD Pharmin-
gen) and CD105-APC (eBioscience, Hatfield, UK).
Alkaline phosphatase activity and cell viability
Cell viability was measured by using CellTiter-Blue Cell
Viability assay in accordance with the instructions of the
manufacturer (Promega). ALP activity was determined
by using a 1 mg/ml solution of P-nitrophenylphosphate
(Sigma-Aldrich) in 50 mM NaHCO3 with 1 mM MgCL2,
pH 9.6, at 37 °C for 20 min; activity was then stopped
with 3 M NaOH. Plates were read by using a FLUOstar
Omega plate reader (BMG Laboratories, Ramcon A/S,
Birkerod, Denmark), and ALP activity was corrected for
cell number.
Cytochemical staining
Cells undergoing osteoblastic or adipocytic induction
were stained at days 5, 10, and 15 for ALP and alizarin
red or Oil red O (ORO), respectively, as previously
described [21]. Elution of ORO staining was performed
by using 100 μl of isopropanol for 10 min at room
temperature; 60 μl was then removed to a 96-well plate
and read on a FLUOstar Omega plate reader set at
500 nm emission wavelength.
Cell morphology analysis by high-content imaging
hMSC-CD146+ and hMSC-CD146− cells were seeded in
96-cell carrier well plates (PerkinElmer, Waltham, MA,
USA) and cultured in standard medium. The adherent
cells were washed with PBS−/−, fixed in 4 % formalde-
hyde for 10 min at room temperature, and washed three
times with PBS. Cells were stained for alpha tubulin,
Phalloidin-TRITC, and Hoechst 33342 (all Sigma-
Aldrich) by using Alexafluor 488 (Thermo Fisher Scien-
tific) as the secondary antibody for alpha tubulin. Plates
were scanned in the Operetta (PerkinElmer) and cells
(>1000 per cell line) analyzed for cell size and shape and
changes in microtubule (F-actin) thickness using the
Harmony software (PerkinElmer) and texture analysis
using SER (saddle, edge, ridge) features to measure
changes in structure within the cell. Both the ‘Valley’
and ‘Ridge’ patterns from the SER features were selected
by using a 2px width to assess spaces or ridge height of
the F-actin fibres.
Boyden chamber transwell migration assay
The migration ability of sorted cells was measured in a
48-well micro-chemotaxis Boyden chamber-based cell mi-
gration assay (8-μm pore polycarbonate membrane; Neuro
Probe, Inc., Gaithersburg, MD, USA). The membrane was
coated for 1 h at 37 °C in migration media—low glucose
Dulbecco’s modified Eagle’s medium (Invitrogen), with
0.2 % FBS (Sigma-Aldrich)—supplemented with 5 μg/ml
Fibronectin and 10 μg/ml rat-tail collagen I. The cells
were cultured in migration media for 24 h prior to migra-
tion initiation. The chemotaxis and control media (27 μl)
were placed in the lower chamber. The chamber was cov-
ered by the coated membrane and fixed by the upper
chamber. Fifty-microliter sorted cells (2.5 × 105 cells/ml
migration media) were loaded into the upper chamber
wells and incubated for 4 h at 37 °C. Non-migrated cells
on the upper side of the membrane were scraped and
rinsed with cold PBS. Migrated cells on the lower side of
the membrane were fixed and stained with a hemacolor®
staining kit (Merck) and imaged on an inverted micro-
scope (×20 magnification). Images were captured of the
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entire wells, and cells were counted by using the ImageJ
program. Results were expressed as mean number of cells
for six technical replicates (n = 2 independent experiments).
Gene expression analysis
Total RNA was extracted from samples collected at days
0, 5, 10, and 15 of induction from unsorted and sorted
populations by using TRIzol (Invitrogen) in accordance
with the instructions of the manufacturer. cDNA was
synthesized by using a revertAid H minus first-strand
cDNA synthesis kit (Fermentas, St Leon-Rot, Germany).
Reverse transcription-polymerase chain reaction (RT-
PCR) was performed on an ABI StepOne™ Real-Time
PCR machine (Life Technologies/Applied Biosystems),
and data analyzed by using Excel (Microsoft Corporation,
Redmond, WA, USA). Ten micrograms of cDNA was
used in each reaction in combination with 2× Fast SYBR
green master mix (Applied Biosystems). Primers were pur-
chased from DNA Technology A/S (Risskov, Denmark) or
Eurofins (Ebersberg, Germany) and included Collagen 1a1
(COL1a1), RUNX2, alkaline phosphatase (ALPL), osteocal-
cin (BGLAP), osteonectin (SPARC), osteopontin (OPN),
the long and short forms of CD146 (lgCD146, shCD146),
CD146, elastin (ELN), decorin (DCN), and biglycan (BGN)
for osteogenic differentiation and adipocyte-specific lipid
binding protein 2 (aP2), PPARγ2, lipoprotein lipase (LPL),
adiponectin (ADIPOQ), and C/CEBPα for adipogenic dif-
ferentiation. Cycle threshold (CT) values were normalized
against β-actin and analysis was performed by using the
comparative CT method. Statistical analysis to detect
differences between gene expression levels was carried out
by using Student’s t test. Primers used in these studies can
be found in Additional file 1: Table S1.
In vivo heterotopic bone formation assay
The cells were trypsinized to a single-cell suspension and
seeded onto 40 mg Triosite (HA/TCP, 0.5- to 1-mm gran-
ules; Biomatlante/Zimmer, Vigneux de Bretagne, France)
and kept overnight at 37 °C, 5 % CO2. HA/TCP granules
in combination with cells were then implanted subcutane-
ously (four implants per cell line) in the dorso-lateral area
of immune-compromised (NOD.CB17-Prkdcscid/J) mice
(The Jackson Laboratory, Bar Harbor, ME, USA) for
8 weeks. Ethical approval for subcutaneous implantations
was granted by the Danish National Animal Experiment
Inspectorate (2012-DY-2934-00006). The implants were
removed, fixed in formalin, decalcified using formic acid
for 3 days or 0.4 M ethylenediaminetetraacetic acid
(EDTA) for 12 days, embedded, and sectioned. Four serial
sections were cut at three different tissue depths with
100 μm distance between each group. Staining was
performed with hematoxylin and eosin (three sections) or
human-specific Vimentin (#RM-9120, Clone SP20; Thermo
Fisher Scientific: one section). Additional staining was
performed by using tartrate-resistant acid phosphate
(TRAP) staining on implants which underwent 0.4 M
EDTA decalcification. In brief, 50 ml acetate buffer pH 5.2
with 115 mg sodium tartrate and 70 mg Fast Red Salt TR
(Sigma-Aldrich, F2768) was mixed with 70 mg napthol AS-
TR phosphate (Sigma-Aldrich, N6125) dissolved in
250 μl N-N-dimethylformamide to produce the staining
solution. The slides with tissue sections were deparaffi-
nized in xylene and processed through increasing alcohol
concentrations before being incubated in the staining so-
lution for 2 h at 37 °C. Sections were briefly counter-
stained in Mayer’s hematoxylin before rinsing in tap water
and mounting under coverslips with an aqueous mounting
medium.
Quantification of heterotopic bone formation and bone
marrow
Mosaic images of serial sections were obtained by using
Surveyor (Objective Imaging, Cambridge, UK). Using
the free-hand contouring tool from PhotoShop (Adobe,
CS4), the tissue area of each implant was calculated.
Using the Magic wand-tool, the bone or BM areas were
highlighted and the areas calculated; data were then
calculated as a percentage of bone or BM/tissue area of
the implant (nine sections per implant).
In vivo migration assay
A closed fracture was created in 10 immunodeficient
(NOD.CB17-Prkdcscid/J; The Jackson Laboratory) 8-week-
old, sedated, female mice (100 mg/kg ketamine hydro-
chloride and 5 mg/kg xylazine hydrochloride) as described
by Bonnarens and Einhorn [22]. Ethical approval for fem-
oral fracture was granted by the Danish National Animal
Experiment Inspectorate (2012-15-2934-00559). Fractures
were created by using a guillotine apparatus on the right
hind limb following insertion of a 0.5-mm needle. Fracture
and pinning were confirmed by x-ray (Faxitron MX-20).
Three hours after fracture, single-cell suspended hMSC-
CD146+ or hMSC-CD146– cells were tail vein-injected at
1 × 106 cells per 100 μl of PBS/injection into five mice per
cell line and bioluminescence imaged at 30 min post-
injection (d0), d1, d3, and d6.
Bioluminescence imaging
The Xenogen IVIS Spectrum (PerkinElmer) was used to
obtain images of bioluminescence. Ten to 15 minutes
prior to imaging, immunodeficient mice, tail vein-injected
with either hMSC-CD146+ or hMSC-CD146− cells, were
injected intraperitoneally with D-luciferin (PerkinElmer,
150 mg/kg body weight in sterile PBS without Mg2+ and
Ca2+) and then sedated with 2.5 % isoflurane in oxygen.
Images were obtained with field-of-view 13.2 cm, binning
factor 8, F/Stop 1, and automatic exposure time by using
Xenogen Living Image™ software (version 2.11) overlay
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(PerkinElmer). Radiance was plotted by using calibrated
measurements of photon emission and displayed in units
of photons/second/cm2/steradian.
Statistical analysis
Three independent in vitro experiments were performed,
and data were presented as mean ± standard deviation.
Statistical analysis were performed by using a one-way
analysis of variance where group size was 3 or more, and
for group sizes of 2, Student’s t test was applied (*P < 0.05,
**P < 0.005 or P < 0.01, ***P < 0.0001).
Results
Characterization of hMSC-LUC2 cell line
hTERT-LUC2 exhibited cell morphology (Additional
file 2: Figure S1A) and CD marker expression profile
(Additional file 2: Figure S1C) similar to hMSC-TERT.
However, hMSC-LUC2 demonstrated lowered prolifera-
tion rate compared with hMSC-TERT: population
doubling per day was 0.45 ± 0.06 versus 0.58 ± 0.04, re-
spectively (P < 0.005) (Additional file 2: Figure S1B). Ex
vivo differentiation studies demonstrated that hTERT-
LUC2 maintained their osteoblastic (Additional file 3: Fig-
ure S2A) and adipocytic (Additional file 3: Figure S2B) dif-
ferentiation capacities. RT-PCR data demonstrated similar
gene expression profiles between the hMSC-TERT and
hTERT-LUC2. Similar to hMSC-TERT, hMSC-LUC2
formed heterotopic bone and BM when implanted sub-
cutaneously in immune-deficient mice (Additional file 4:
Figure S3).
Isolation and phenotypic characterization of hMSC-CD146
+ and hMSC-CD146– cells
hMSC-LUC2 cells (18 × 106) were sorted on the basis of
the expression of CD146. Two distinct areas were gated
(P4: hMSC-CD146+ and P5: hMSC-CD146–; Fig. 1a), and
cells remaining within the intermediary area (40 % of the
total population) were discarded. After sorting of the
Fig. 1 Flow cytometric cell sorting and cell characterization. a Details from FacsDIVA sorting demonstrating the overall distribution of CD146 in
hMSC-TERT and the gated CD146+ (P4) and CD146− (P5) populations. b Flow cytometric validation of the hMSC-CD146+ and hMSC-CD146−
populations and expression of canonical mesenchymal stem cell (MSC) markers: CD44, CD63, CD73, CD105, CD14, CD34, and CD146. c Analysis
of population doublings demonstrating no significant difference between the different cell populations. FSC-A forward scatter-A, hMSC human
mesenchymal stem cell
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hMSC-CD146+ cells, 75.5 % were gated within P4 and
89.1 % of cells were gated within P5 (hMSC-CD146–)
(Fig. 1a). Immediately after cell sorting and for subsequent
passages when cells were used for experimental purposes,
flow cytometry was performed to confirm the CD146 status
in both cell populations. The cells maintained their CD146
+ or CD146− status for six passages. In addition, the MSC
identity of the cells was maintained as shown by the expres-
sion of a selected number of CD markers by FACS analysis:
CD14 and CD34 (both negative) and CD44, CD63, CD73,
and CD105 (all positive). We observed similar expression
levels of these markers in hMSC-CD146+ and hMSC-
CD146– (Fig. 1b). Growth rate was identical between
hMSC-LUC2, hMSC-CD146+, and hMSC-CD146–
(Fig. 1c).
Quantitative cell morphology using high-content imaging
hMSC-CD146+ and hMSC-CD146– were examined for
their differences in cell morphology and texture using
high-content imaging analysis. Significant differences in
cell area, roundness, and width-to-length ratio were ob-
served between hMSC-CD146+ and hMSC-CD146−
(Fig. 2). hMSC-CD146+ were rounder than hMSC-
CD146− cells and demonstrated a smaller cytoplasmic
area. Analysis of the F-actin filaments (stained with
Phalloidin) using SER texture analysis demonstrated that
the hMSC-CD146− cells contained significantly larger
fibres than hMSC-CD146+ (P < 0.05; Fig. 2).
Osteoblast differentiation of hMSC-CD146+ and hMSC-
CD146–
No consistent significant differences between gene expres-
sion levels in hMSC-CD146+ and hMSC-CD146– were
observed (Fig. 3a). Similarly, no differences were observed
between hMSC-CD146+ and hMSC-CD146– in ALP ac-
tivity (Fig. 2b) or ALP cytochemical staining (Fig. 3c) or in
their ability to form mineralized matrix as visualized by
Fig. 2 Morphological and texture studies using high-content single-cell imaging. Fluorescent staining of hMSC-TERT, hMSC-CD146+, and hMSC-
CD146− (n = 3) demonstrates morphological changes assessed by tubulin and F-actin staining. Significant changes are demonstrated in cell
roundness, area, and width-to-length ratio (*P < 0.05). Changes in F-actin are demonstrated by analysis of depth and height of ridges of the actin
fibres. *P < 0.05. Scale bar = 100 μm. hMSC human mesenchymal stem cell, SER saddle, edge, ridge
Harkness et al. Stem Cell Research & Therapy  (2016) 7:4 Page 6 of 13
Fig. 3 (See legend on next page.)
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alizarin red staining (Fig. 3c). The phenotype of hMSC-
CD146+ and hMSC-CD146– was stable during osteoblast
differentiation as demonstrated by gene expression levels
of CD146 isoforms (Fig. 3a).
CD146 was previously reported to have two iso-
forms—short and long, generated by alternative splicing
of the cytoplasmic region—which probably mediate dif-
ferent functions [23]. We found that the long form of
CD146 (lgCD146), but not the short form (shCD146),
expression levels were upregulated during OB differenti-
ation (P < 0.05) (Fig. 3a).
Adipocytic differentiation of hMSC-CD146+ and hMSC-
CD146–
Both hMSC-CD146+ and hMSC-CD146– exhibited simi-
lar differentiation capacity to adipocytes as revealed by
comparable gene expression levels of adipocytic differen-
tiation markers: peroxisome proliferator-activated recep-
tor gamma 2 (PPARγ2), lipoprotein Lipase (LPL), fatty
acid binding protein 4 (FABP4/aP2), CCAAT/enhancer
binding protein alpha (C/EBPα), adiponectin (ADIPOQ)
as well as oil red O staining of mature adipocytes and
quantitative measurements of eluted oil red O as an in-
dicator of the number of mature, lipid filled adipocytes
(Additional file 5: Figure S4).
In vivo heterotopic bone formation
We examined the ability of hMSC-CD146+ and hMSC-
CD146– populations to form heterotopic bone when
implanted subcutaneously in immune-deficient mice to-
gether with HA/TCP. The CD146 status of the cells was
confirmed by flow cytometry prior to implantation
(Additional file 6: Figure S5). Bone formation was dem-
onstrated in both hMSC-CD146+ and hMSC-CD146–
(Fig. 4). Formation of BM within the implants was iden-
tified on the basis of the presence of large sinusoids
(Fig. 4d-f ) and BM elements (Fig. 4g-i, m). Quantifica-
tion of bone formation demonstrated a significant differ-
ence between hMSC-CD146− (12.6 ± 1.5) and hMSC-
CD146+ (8.1 ± 1.0) (P < 0.05) (Fig. 4o). In contrast, sig-
nificantly (P < 0.01) increased amounts of BM were iden-
tified in hMSC-CD146+ (0.5 % ± 0.2 %) as compared
with hMSC-CD146– (0.05 ± 0.02) (Fig. 4p). Scans of
whole implants demonstrating differences in bone for-
mation between hMSC-CD146+ and hMSC-CD146− can
be found in Additional file 7: Figure S6. Specificity of the
vimentin staining was demonstrated by using murine
MSCs implanted under similar conditions to hMSCs
(Additional file 8: Figure S7). Bone formed in hMSC im-
plants was of human origin as evidenced by positive
staining for a human-specific vimentin (Fig. 4j-l).
In vitro and in vivo chemotaxis assay
To explore other biological characteristics associated
with the CD146 status, we examined the cells’ ability for
chemotaxis in vitro and in vivo. The hMSC-CD146+
sorted population exhibited enhanced chemotactic re-
sponses to 10 % FBS when compared with the 0.2 % FBS
control in an in vitro transwell migration assay. In con-
trast, hMSC-CD146− cells demonstrated no significant
migration between 0.2 % (control) and 10 % FBS
(Fig. 5a). To examine the in vivo relevance of this obser-
vation, we injected LUC2-labelled hMSC-CD146+ and
hMSC-CD146– into the tail vein of immune-deficient
mice with prior closed femur fracture. The mice were
examined at d0, d3, and d6 (Fig. 5b). In all mice injected
with hMSC-CD146–, the cells migrated to the lung,
where the majority remained throughout the 6-day
period. In contrast, hMSC-CD146+ cells were observed
to migrate away from the lung area starting at day 3 and
were recruited to both the injured right leg and non-
injured left leg. By day 6, hMSC-CD146+ exhibited
wider systemic distribution throughout the animals.
Analysis of the bioluminescence radiance captured by
using IVIS imaging demonstrated statistically significant
differences between the lung and lower body radiance.
Data from the lung radiance demonstrated a shift
from significantly higher levels of hMSC-CD146+ ra-
diance at d0 (P < 0.05) to significantly lower radiance
at day 6 (P < 0.01) as compared with hMSC-CD146−.
Analysis of the lower body demonstrated significantly
increased radiance in the hMSC-CD146+ at all time
points (*P < 0.05, **P < 0.01) as compared with hMSC-
CD146− radiance.
Discussion
Identification of prospective markers defining the func-
tional ability of hMSCs is an important pre-requisite for
use of hMSCs in therapy. In the present study, we
employed CD146 to functionally phenotype BM hMSCs.
Our results demonstrate that CD146 defines a popula-
tion with bone-forming capacity as well as ability for in
vivo trans-endothelial migration and homing to injured
bone sites.
(See figure on previous page.)
Fig. 3 Characterization of sorted CD146 populations undergoing osteoblast (OB) differentiation. a Reverse transcription-polymerase chain reaction
data (mean ± standard error of the mean, n = 3 independent experiments) analyzed from sorted population at day (d) 0, 5, 10, and 15. *P < 0.05.
sh = short form and lg = long form of CD146. b Alkaline phosphatase (ALP) activity/cell viability at d6 of osteoblastic differentiation. c ALP staining
at d6 and d10 of OB differentiation. Alizarin red (AZR) staining at d10 and d15 of OB differentiation. n = 3 independent experiments. white box,
hMSC-CD146+; black box, hMSC-CD146−; gray box, lgCD146+
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Previous studies have suggested a number of biological
roles for CD146, including trans-endothelial migration
[24–27], cell proliferation regulation [27–29], and a role
in cancer metastases [30–32]. In addition, CD146 has
also been proposed as a pericyte cell marker [33, 34]
and as a cell marker for hMSCs and osteoblastic cells
[27, 33, 35]. Here, we report that CD146 status is asso-
ciated with progenitor functions of hMSCs which in-
clude differentiation into osteoblasts and adipocytes as
well as ability for trans-endothelial migrations in vivo.
Both hMSC-CD146+ and hMSC-CD146− cells were
able to differentiate readily into osteoblastic and adipo-
cytic cells with similar efficiency, and both populations
formed heterotopic bone and BM when implanted in
immune-deficient mice. Our results corroborate previ-
ous results that also demonstrated, in primary BM
hMSCs, that CD146 status did not influence response to
differentiation induction to osteoblasts, adipocytes, or
chondrocytes [28]. Recently, Gothard et al. compared
CD146+ cells with Stro1+ and demonstrated similar gene
expression profiles [13]. Similarly, Russell et al. reported
that CD146+ cells are enriched in multipotent hMSCs
[7]. Although these studies did conduct side-by-side
comparison of CD146+ and CD146− hMSC populations,
the current data suggest that CD146+ status defines the
progenitor cell population of hMSCs.
Morphological changes of the cytoskeleton, including
reorganization of actin fibres, are important for osteo-
blast cell differentiation [36]. Recent data have demon-
strated an increase in the density of F-actin during
hMSC differentiation [37]. Using the SER features from
the Harmony software, we analyzed the cytoplasmic tex-
ture and demonstrated significant differences in the sizes
of the F-actin fibres between hMSC-CD146+ and hMSC-
CD146− cells, and actin fibres were significantly larger in
the hMSC-CD146− population. Sonowal et al. [38],
McBeath et al. [39], and Treiser et al. [40] have reported
an association between actin fibre and cytoskeletal modi-
fication with osteoblastic differentiation. Thus, the ob-
served changes in actin fibres in CD146− cells may
contribute to their more mature OB phenotype.
We identified that CD146 defines cells with ability
for trans-endothelial migration. Statistically significant
data demonstrated that hMSC-CD146+ cells migrated
away from the lungs; however, homing to a site of
injury was not consistently observed. Consistent with
these findings, we observed that the hMSC-CD146+ cells
exhibited a smaller cell size and cytoskeletal morphology,
suggesting enhanced motility. Our results corroborate
results from previous investigators that CD146 confers
additional functional phenotype on hMSCs. Espangolle et
al. reported that CD146+ cells exhibited an enriched vas-
cular smooth muscle cell phenotype [28]. Ye et al. [26]
demonstrated that CD146 acts as a receptor for Wnt5A,
mediating induced cell migration. Along similar lines to
our study, Blocki et al. [33] reported that although both
CD146+ and CD146− populations of BM hMSCs exhibited
an equivalent differentiation ability for adipogenic and
osteoblastic lineages, only CD146+ cells formed endothe-
lial tubular networks on Matrigel™. The endothelial-like
phenotype may be related to trans-endothelial migration
ability.
We identified a significant difference between the
amount of bone formed by hMSC-CD146+ and hMSC-
CD146− cells. hMSC-CD146− formed more bone but
demonstrated a 10-fold decrease in BM compared with
hMSC-CD146+. hMSC-CD146− maintained their CD146−
status throughout the experiments, but hMSC-CD146+
cells were observed to be returning to a phenotypic equi-
librium after six passages post-cell sort. Thus, it is possible
that utilization of cells where 100 % were positive for
CD146 may enhance the quantity of BM and decrease the
amount of bone formed. Previous reports have demon-
strated that CD146+ hMSCs are located in the perivascu-
lar spaces [14] and have been associated with re-
establishment of the haematopoietic microenvironment
[18]. In comparison, CD146− cells were found to line the
bone cavity [14]. The different locations of CD146+ or
CD146− cells could suggest that, within the heterogeneous
MSC population, cells have different degrees of maturity:
CD146− form more bone and less marrow and are thus
more mature, whereas CD146+ retain more plasticity (that
is, in addition to bone formation and BM formation, they
have a trans-endothelial migration capacity).
Conclusions
We hypothesize that CD146+ cells are recruited to bone
surfaces by trans-endothelial migration [41]. Further
maturation to active osteoblasts is associated with loss
of CD146 and thus cells located on active bone-forming
surfaces are CD146−. Changes in the expression of
CD146 reveal a dual function in hMSC biology: a role
(See figure on previous page.)
Fig. 4 In vivo heterotopic bone formation. hMSC-LUC2 (a, d, g, j, m), hMSC-CD146+ (b, e, h, k), and hMSC-CD146− (c, f, i, l) were implanted
subcutaneously (n = 4) mixed with hydroxyapatite tricalcium phosphate/Triosite (HA/TCP) into immune-compromised mice for 8 weeks. Analysis
was performed on three serial sections at three depths with 100 μm between each depth. Hematoxylin and eosin (H&E) staining of bone
formation demonstrating distribution of bone within the implants (a-i, m). d-f Blood vessel formation within the implants. g-i Establishment of
bone marrow within the implants. j-l Human-specific vimentin staining of developing bone demonstrating the human origin. o, p Quantification
of total bone or bone marrow volume. Scale bar on all H&E and vimentin staining = 100 μm
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in enhancing migration and recruitment to bone sur-
faces (CD146+) and a role in osteoblastic commitment
and bone formation (CD146−). Further studies examin-
ing molecular details of mechanisms underlying these
two functions need to be investigated.
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A Osteoblastic differentiation. B Adipocytic differentiation. *P < 0.05,
**P < 0.005, ***P < 0.001; scale bar = 100 μm: black box, hMSC-TERT; white
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Additional file 4: Figure S3. Characterization and comparison of in vivo
bone formation of hMSC-TERT and hMSC-LUC2. A, B Scanned images of
hMSC-TERT and hMSC-LUC2 implants. Hematoxylin-and-eosin staining of
hMSC-TERT (C) and hMSC-LUC2 (D). E hMSC-LUC2 implants: human-
specific vimentin staining demonstrating the human origin of the cells.
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Additional file 5: Figure S4. In vitro adipocytic differentiation of
hMSC-CD146+ and hMSC-CD146− cell populations. A Oil red O staining.
B Reverse transcription-polymerase chain reaction analysis of adipocytic
gene expression. n = 3 independent experiments, mean ± standard error
of the mean; white box, hMSC-CD146+; black box, hMSC-CD146−; scale
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Additional file 6: Figure S5. CD profile of hMSC-TERT, hMSC-CD146+,
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human mesenchymal stem cell. (TIF 150 kb)
Additional file 7: Figure S6. Scanned images (hematoxylin and eosin
and human-specific vimentin) of whole implants of hMSC-CD146+ and
hMSC-CD146− cells implanted into immune-compromised mice for
8 weeks. Cells of murine origin can be observed in the non-stained areas
of implants as demonstrated by arrows. hMSC human mesenchymal stem
cell. (TIF 1385 kb)
Additional file 8: Figure S7. Validation of human-specific vimentin
staining. A, B Human mesenchymal stem cells (hMSCs) implanted on
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